These four Buy-rated stocks are trading under $10 and could offer patient investors enormous returns for 2025 and beyond.
Analysts from Canaccord Genuity, Roth/MKM, and Northland have all given positive ratings for the company. Canaccord Genuity maintained a Buy rating with an adjusted price target to $11.00, while ...
Sean Murphy, Chief Manufacturing, Strategy & Business Development Officer and Director at TriSalus Life Sciences Inc. (NASDAQ ...